Vorapaxar for the reduction of atherothrombotic events.

• Autores: A.M. Díaz, Ginés Escolar Albadalejo
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 50, Nº. 11, 2014, págs. 747-756
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Vorapaxar is a novel platelet inhibitor that potently and selectively inhibits thrombin-mediated platelet activation without interfering with thrombin-mediated cleavage of fibrinogen via antagonism of the platelet proteinase-activated receptor PAR1. Vorapaxar is a non-peptide himbacine analogue that has been developed for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral arterial disease.